Friday, July 10, 2026

pharma · Motor fluctuations in advanced Parkinson’s disease · Non Cystic Fibrosis Bronchiectasis

ZAMBON S.P.A

Zambon SpA is a pharma organization headquartered in EU. Primary therapeutic focus areas include Motor fluctuations in advanced Parkinson’s disease, Non Cystic Fibrosis Bronchiectasis. NovaPharmaNews links 3 clinical pro

IT HQ
8 Employees
EMA registrant Type
Company details
Status
Public
HQ
IT
Employees
8
Programs
3
Drugs
7
Patents
0
Clinical program

ZB203L01

Phase 3 · small molecule · Motor fluctuations in advanced Parkinson’s disease

ZB203L01 for Motor fluctuations in advanced Parkinson’s disease is a Phase 3 program (small_molecule) at Zambon SpA with 1 ClinicalTrials.gov record(s).

← All Zambon SpA projects Phase 3 small molecule active

Internal code ZB203L01

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Zambon SpA
Phase
Phase 3
Modality
small_molecule
Indication
Motor fluctuations in advanced Parkinson’s disease
Status
active
Trials
1